This inventor holds 37 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Hoechst Aktiengesellschaft, Other. Active years: 1976-2000.
Location History:
- Kelkheim, Taunus, DE (1976 - 1977)
- Kelkheim/Taunus, DE (1992 - 1995)
- Kelkheim, DE (1979 - 2000)
Company Filing History:
36 out of 6,662 
1 out of 834,307 Years Active: 1976-2000
Areas of Expertise:
Title: Ernold Granzer: Innovator in Pharmaceutical Development
Introduction
Ernold Granzer is an accomplished inventor based in Kelkheim, Germany, known for his significant contributions to the field of pharmaceuticals. With an impressive portfolio of 37 patents, Granzer has focused on developing innovative solutions for various medical and therapeutic applications. His work showcases the importance of research and innovation in advancing healthcare.
Latest Patents
Granzer's latest patents include groundbreaking formulations such as polyaspartamide derivatives designed as adsorbents for bile acids. These compounds have been described in detail in his patents, which highlight the process of their preparation and their potential use as pharmaceuticals. His work with α- or β-linked polyaspartamide derivatives demonstrates the versatility of these compounds in treating bile acid interactions. Additionally, Granzer has developed soluble salts of 4-amino-2-(4,4-dimethylimidazolidin-2-on-1-yl)pyrimidine-5-carboxylic acid, which show promise for treating lipid metabolism disorders by stimulating hepatic LDL receptor activity.
Career Highlights
Throughout his career, Ernold Granzer has worked with notable organizations, including Hoechst Aktiengesellschaft, where he contributed to pharmaceutical innovations and advancements. His vast experience combines both practical applications in the industry and research-driven solutions, making him a valuable asset in the field of medicinal chemistry.
Collaborations
Granzer has collaborated with esteemed colleagues such as Wilhelm Bartmann and Hans-Jochen Lang, further enriching his research and innovation endeavors. These collaborations have allowed for a cross-pollination of ideas, leading to the development of more effective pharmaceutical solutions.
Conclusion
Ernold Granzer's dedication to innovation in pharmaceuticals is evident through his extensive patent portfolio and collaborative efforts. His groundbreaking work with polyaspartamide derivatives and other compounds illustrates the vital role of inventors in enhancing healthcare solutions. As Granzer continues to innovate, his contributions will undoubtedly make a lasting impact in the realm of therapeutic pharmaceuticals.